医生头像

樊东升   主任医师 教授

收藏本站

本站已经通过实名认证,所有内容由樊东升大夫本人发表

当前位置: 北医三院 > 樊东升 > 文章列表 >雷沙吉兰治疗ALS的初步研究

学术前沿

雷沙吉兰治疗ALS的初步研究 (转载)

发表者:樊东升 人已读

A multi-center screening trial of rasagiline in patients with ALS: Possible mitochondrial biomarker target engagement

Zachary MacchiaYunxia WangaDan Mooreb,Jonathan KatzbDavid SapersteincDavid Walkd,Ericka SimpsoneAngela GengefTulio BertorinigJ. Americo FernandeshAndrea SwensoniLauren ElmanjMazen DimachkieaLaura HerbelinaJoann MilleraJianghua LuaHeather WilkinsaRussell H. SwerdlowaJeffrey StatlandaRichard Barohna* & the Western ALS (WALS) Rasagiline Study Groupk北京大学第三医院神经内科樊东升

Abstract

Rasagiline, a monoamine oxidase B inhibitor, slowed disease progression in the SOD1 mouse, and in a case series of patients with amyotrophic lateral sclerosis (ALS). Here we determine whether rasagiline is safe and effective in ALS compared to historical placebo controls, and whether it alters mitochondrial biomarkers. We performed a prospective open-label, multicenter screening trial of 36 ALS patients treated with 2 mg oral rasagiline daily for 12 months. Outcomes included the slope of deterioration of the revised ALS Functional Rating Scale (ALSFRS-R), adverse event monitoring, time to treatment failure, and exploratory biomarkers. Participants experienced no serious drug-related adverse events, and the most common adverse event was nausea (11.1%). Rasagiline did not improve the rate of decline in the ALSFRS-R; however, differences in symptom duration compared to historical placebo controls differentially affected ALSFRS-R slope estimates. Rasagiline changed biomarkers over 12 months, such that the mitochondrial membrane potential increased (JC-1 red/green fluorescent ratio 1.92, p = 0.0001) and apoptosis markers decreased (Bcl-2/Bax ratio 0.24, p < 0.0001). In conclusion, engagement of exploratory biomarkers and questions about comparability of baseline characteristics lead us to recommend a further placebo-controlled trial.

问医生

网上免费问医生开始

发表于:2015-10-07 00:28

发表评论

樊东升大夫的信息

  • 感谢信: 0 感谢信 礼物: 0 礼物
  • 贡献值: 0

网上咨询樊东升大夫

樊东升医生暂时不接受网络咨询

樊东升的咨询范围: 运动神经元病